title: Chimeric fibrolase: covalent attachment of an RGD-like peptide to create a potentially more effective thrombolytic agent.
abstract: We have prepared an agent possessing both thrombolytic and antiplatelet properties, by conjugating fibrolase, a direct-acting fibrinolytic enzyme isolated from southern copperhead venom, to a peptide which inhibits platelet aggregation. Heterobifunctional coupling reagents, N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP) or sulfosuccinimidyl 6-[alpha-methyl-alpha-(2-pyridyldithio)-toluamido]hexanoate (Sulfo-LC-SMPT), were used in a molar ratio of 10:1 (coupling agent/fibrolase). The N-hydroxy-succinimide of the coupling agent reacts with surface epsilon-amino groups of lysine residues on fibrolase and provides a dithio group that is highly reactive with small thiol compounds. The derivatives obtained in the first reaction contain approximately two moles of 2-pyridyl disulphide per mole of enzyme. These derivatives were then reacted with the free thiol group in an antiplatelet peptide at a molar ratio of 2:1 (peptide/fibrolase). The peptide-fibrolase conjugate was purified by cation exchange HPLC and analyzed by amino acid analysis. The conjugate contains one mole peptide per mole of fibrolase and retains approximately 85% fibrinolytic activity. The IC50 for inhibition of platelet aggregation in human PRP is 300 nM for the conjugate and 67 nM for the antiplatelet peptide. These results demonstrate the successful formation of a novel chimeric protein with bifunctional activity.
authors.affiliation: Department of Biochemistry and Molecular Biology, University of Southern California, School of Medicine, Los Angeles 90033, USA.
authors.forename: E F
authors.initials: EF
authors.lastname: Sanchez
authors.forename: L R
authors.initials: LR
authors.lastname: Bush
authors.forename: S
authors.initials: S
authors.lastname: Swenson
authors.forename: F S
authors.initials: FS
authors.lastname: Markland
mesh_terms: D000818:Animals; D002364:Caseins / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid; D015195:Drug Design; D005337:Fibrin / Q000378:metabolism; D005343:Fibrinolytic Agents / Q000737:chemistry* / Q000494:pharmacology; D006801:Humans; D008666:Metalloendopeptidases / Q000737:chemistry* / Q000494:pharmacology; D015394:Molecular Structure; D009842:Oligopeptides / Q000737:chemistry* / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000737:chemistry* / Q000494:pharmacology; D011993:Recombinant Fusion Proteins / Q000737:chemistry* / Q000494:pharmacology
chemical_list: D002364:Caseins; D005343:Fibrinolytic Agents; D009842:Oligopeptides; D010975:Platelet Aggregation Inhibitors; D011993:Recombinant Fusion Proteins; C026018:azocasein; C047981:arginyl-glycyl-aspartic acid; D005337:Fibrin; D008666:Metalloendopeptidases; C058789:fibrolase